BIOASIS TECHNOLOGIES INC (BTI.CA) Stock Overview
Canada - TSX-V:BTI - CA09064N1033 - Common Stock
BTI.CA Key Statistics, Chart & Performance
The current stock price of BTI.CA is 0.005 CAD. In the past year, price decreased by -92.31%.
BTI.CA Latest News, Press Relases and Analysis
BTI.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 434.79M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 379.50M | ||
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 333.96M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 164.98M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 123.45M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 28.38 | 62.24M | ||
| NRX.CA | NUREXONE BIOLOGIC INC | N/A | 57.76M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.88M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 30.06M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 25.81M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 17.48M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 11.63M |
Related stock screener links
About BTI.CA
Company Profile
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Burnaby, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). The company is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The firm is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.
Company Info
BIOASIS TECHNOLOGIES INC
22420 Dewdney Trunk Road, Suite 300
Burnaby BRITISH COLUMBIA 06437 CA
CEO: Deborah Ann Rathjen
Employees: 0
Phone: 12035337082
BIOASIS TECHNOLOGIES INC / BTI.CA FAQ
What does BTI do?
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Burnaby, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). The company is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The firm is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.
Can you provide the latest stock price for BIOASIS TECHNOLOGIES INC?
The current stock price of BTI.CA is 0.005 CAD.
Does BIOASIS TECHNOLOGIES INC pay dividends?
BTI.CA does not pay a dividend.
How is the ChartMill rating for BIOASIS TECHNOLOGIES INC?
BTI.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Should I buy BTI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BTI.CA.
What is the market capitalization of BTI stock?
BIOASIS TECHNOLOGIES INC (BTI.CA) has a market capitalization of 397.07K CAD. This makes BTI.CA a Nano Cap stock.
What is the next earnings date for BTI stock?
BIOASIS TECHNOLOGIES INC (BTI.CA) will report earnings on 2022-01-26.
BTI.CA Technical Analysis
BTI.CA Financial Highlights
Over the last trailing twelve months BTI.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 21.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -163.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTI.CA Forecast & Estimates
For the next year, analysts expect an EPS growth of -16.67% and a revenue growth 215.79% for BTI.CA